Literature DB >> 35095364

SELF-REPORTED OLFACTORY, GUSTATORY AND OTOLOGIC DYSFUNCTIONS AMONG COVID-19 POSITIVE ADULTS IN NIGERIA- A PRELIMINARY REPORT.

A J Fasunla1, Y Thairu2, H Salami3, T S Ibekwe4.   

Abstract

INTRODUCTION: The pathophysiology of COVID-19 is evolving. We investigated self-reported sudden loss of sense of smell and taste, and otologic disorders among COVID-19 patients.
METHODS: This was a case-control olfaction, gustation and otology study of COVID-19 RT-PCR tested adults. The study took place at the isolation centres for COVID-19 positive individuals in Abuja and Ibadan, among the epicentres of the disease in Nigeria. The participants were 46 COVID-19 positive adults and 46 COVID-19 negative adults. They responded to a validated online questionnaire-based on olfactory, gustatory and auditory loss. Chi-square tests and correlation analysis was done. Level of significance was at P<0.05.
RESULTS: Among cases, sudden loss of smell, taste and hearing were reported by 14 (30.4%), 8 (17.4%) and 5 (10.9%) cases respectively during the COVID- 19 infection. First symptom was loss of smell in 7 (15.2%) and loss of taste in 2 (4.3%) cases. The controls did not present with any of the symptoms. There was no significant correlation between loss of smell and age (r = 0.023, p=0.879); sex (r = -0.132, p=0.382) and co-morbidities (r = -0.028, p = 0.857). Similarly, there was no significant correlation between loss of taste and age (r = 0.052, p = 0.732); sex (0.040, p = 0.792) and co-morbidities (r = -0.014, p = 0.925).
CONCLUSION: Sudden loss of smell and taste are commoner among COVID - 19 positive adults than those without the infection in Nigeria. There is evidence of associated reduction in hearing acuity but further study with objective audiometric testing is recommended. © Association of Resident Doctors, UCH, Ibadan.

Entities:  

Keywords:  Ageusia; Anosmia; COVID-19 pandemic; Chemosensory dysfunction; Coronavirus; Hearing loss; Otology; SARS-CoV-2

Year:  2021        PMID: 35095364      PMCID: PMC8791404     

Source DB:  PubMed          Journal:  Ann Ib Postgrad Med


INTRODUCTION

Corona virus disease-2019 (COVID-19) is an RNA-viral syncytial respiratory disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 was first reported in Wuhan, China at the twilight of 2019 and declared a pandemic by the World Health Organisation (WHO) in March 2020. The epidemiology and management of this illness is still evolving resulting in the recent recognition of smell and taste disorders as "minor" clinical presentations in COVID-19 patients by the WHO, Centres for Disease Control and Prevention (CDC) and other global health organizations.[1] Coronavirus is a highly virulent and contagious organism with an incubation period of about 2 weeks within which asymptomatic patients can transmit the disease. It is difficult to identify carriers and asymptomatic patients during the incubation period hence the prescribed stringent measures such as social distancing, hand washing, wearing of face masks, etc., to prevent, control, and contain its spread.[2] Common symptoms of COVID-19 were fever, difficulty with breathing and cough. Early presentations with loss of smell (anosmia) and/or taste (ageusia) in mild and moderate cases of COVID-19 could be a red-flag and veritable tool for early diagnosis.[3] It is true that several diseases caused by viruses such as Herpes Simplex, Rhinoviruses, Measles, Epstein-Barr, Chicken pox and other Coronaviruses present with varying degrees of anosmia, rhinorrhoea and nasal blockage.[4,5] Sometimes these triad is associated with ageusia. However, the anosmia and ageusia associated with COVID-19 is typically without rhinorrhoea or nasal blockage.[6] In addition, patients with COVID-19 have more than 10-fold chance of developing ageusia and anosmia compared to other flu-like diseases.[7] Variable reports on anosmia and ageusia in COVID-19 patients were documented in different parts of the world with the exception of Africa.[3,5-9] SARS-CoV-2 infects human through the nasal cavity, oral cavity and conjunctiva. The respiratory epithelium and its supporting olfactory cells are rich in Angiotensin Converting Enzyme-2 (ACE2). This feature makes them serve as reservoir for the replication of the SARS-COV-2 virus because the spike (S) proteins on their cell walls called protease transaminase protease serine-2 (TMPRSS2) have strong affinity for ACE2.[3] This interaction initiates an inflammatory process in the olfactory and respiratory epithelium. Contiguous anatomical relationship and similarity in the epithelial cells of the nasal cavities/nasopharynx, the Eustachian tube and the middle ear strongly suggest a middle ear cleft susceptibility to COVID-19. Above all, SARS-COV-2 has been isolated in the middle ear spaces and mastoid cavities of COVID-19 patients.[10] The exact pathophysiology of loss of smell and taste in COVID-19 is not known. However, nasal mucosa inflammation, damage to olfactory receptors and infection of the olfactory bulb, nerve and smell centre in the brain have been suggested as the possible mechanisms.[11-13] Any or all of these three mechanisms may be possible for loss of smell and by extension taste in the COVID-19 though subject to further investigation. To the best of our knowledge, there has not been any clinical report on otologic manifestations of COVID-19 at the time of design of this research. To this end, we set out to explore the features of selfreported anosmia, ageusia and otological disorders among COVID-19 patients.

METHODS

This was a case-control olfaction, gustation and otology study of COVID-19 tested patients using real-time reverse transcription polymerase chain reaction (RTPCR). Test cases were COVID-19 positive patients and controls were COVID-19 negative contacts. Criteria for testing by the test centres were based on either exhibition of symptoms or contact with a COVID-19 positive patient. The test centres were in Abuja which is one of the epicentres of the disease in Nigeria and Ibadan. Contact details of the participants who had undergone COVID-19 testing was collected from these centres after obtaining permission from the head of Isolation/Treatment Centre of University of Abuja Teaching Hospital, Gwagwalada and University of Ibadan. Thereafter, participants were contacted via telephone and only those who gave informed consent were recruited into the study. A structured, self-administered questionnaire was sent to them physically through the frontline workers at the centres to obtain their information on sociodemographics, travel history, symptomatology of COVID-19, the first symptom manifested and its duration, presence of loss of smell, taste, hearing, as well as medical comorbidities, treatment received, etc. Each participant subjectively graded his/her degree of loss of smell, taste and hearing on a visual analogue scale from 1 to 10. A score of 1 – 3 is regarded as mild, 4 – 7 is regarded as moderate and 8 – 10 is regarded as severe.

Data analysis/calculations

An anonymised database was used for analysis. Proportions were compared using Chi-square with Yates' correction or Fisher's exact tests. Normally distributed, continuous variables were compared by Student's t-test for independent group. The relationship between COVID-19 and loss of smell, taste and hearing was analysed using Pearson's correlation Coefficient. Descriptive data was presented and level of significance was determined at P<0.05, two-tailed level at 95% Confidence Interval (CI) and correlation coefficient (r).

RESULTS

Sociodemographic characteristics

Forty-six COVID-19 positive adults comprising 25 (54.3%) males and 21 (45.7%) females as well as 46 COVID-19 negative adults comprising 31 (67.4%) males and 15 (32.6%) females completed and returned the questionnaire. The mean age of 37.6±14.8 years in COVID-19 positive adults and 40.2±14.3 years in COVID-19 negative adults was similar. The country of residence in the preceding six months by the participants was shown in table 1; 15 (32.6%) cases had travelled outside Nigeria while all the controls have no abroad travel history. Majority 33(71.7) of the COVID-19 positive adults belong to the high socioeconomic class while only 13(28.3) controls belong to high socioeconomic class (Table 1). Social Classification was based on Oyedeji’s Social Classification 2007.[14]
Table 1:

Socio-demographic variables of the participants

VariablesParticipants

CasesControlsTotal
n=46n=46n=92
n (%)n (%)n (%)

Age 37.6±14.8¥ 40.2±14.3¥
Male 25(54.3) 31(67.4) 56(60.9)
Female 21(45.7) 15(32.6) 36(39.1)
Country of Residence
Nigeria 31(67.4) 46(100.0) 77(83.7)
UK 8(17.4) 0(0.0) 8(8.7)
USA 4(8.7) 0(0.0) 4(4.3)
Germany 1(2.2) 0(0.0) 1(1.1)
Turkey 1(2.2) 0(0.0) 1(1.1)
China 1(2.2) 0(0.0) 1(1.1)
Socioeconomic status
High 33(71.7) 13(28.3) 46(50.0)
Middle 12(26.1) 18(39.1) 30(32.6)
Low 1(2.2) 15(32.6) 16(17.4)

Mean±SD

The symptomatology of the COVID-19 positive adults is shown in table 2. Sixteen (34.8%) of them presented with cough and body aches while fever, tiredness and difficulty with breathing were reported by 12 (26.1%), 8 (17.4%) and 4 (8.7%) cases respectively. Loss of smell was reported by 14 (30.4%) and loss of taste was reported by 8 (17.4%) cases. The controls did not present with any of the symptoms in table 2.
Table 2:

Clinical characteristics of the COVID-19 positive adults

Symptoms Frequency(N=46) Percent

Cough 16 34.8
Body aches 16 34.8
Sudden loss of smell 14 30.4
Fever 12 26.1
Abdominal pain 11 23.9
Sudden loss of taste 8 17.4
Tiredness 8 17.4
Loss of appetite 6 13
Headache 5 10.9
Rhinorrhea 5 10.9
Difficulty with breathing 4 8.7
Chest pain 1 2.2
The first symptom manifested by the cases was shown in table 3. Seven (15.2%) cases have either sudden loss of smell or cough as their first symptom. Fever was the first symptom in 6 (13%) cases, tiredness and sudden loss of taste were reported as first symptom in 2 (4.3%) cases.
Table 3:

First symptom of COVID-19 as reported by the participant

Symptoms Frequency (N=46) Percentage

Sudden loss of smell 7 15.2
Cough 7 15.2
Fever 6 13
Body aches 5 10.9
Headache 4 8.7
Abdominal pain 4 8.7
Loss of appetite 4 8.7
Sudden loss of taste 2 4.3
Tiredness 2 4.3
Chest pain 1 2.2
Rhinorrhea 1 2.2
Difficulty with breathing 1 2.2
No response 2 4.3
Only few respondents reported medical comorbidities. Among the cases, only 2 (4.3%) respondents had history of hypertension while among the controls, 1 (2.2%) was asthmatic and 1 (2.2%) was diabetic.

Prevalence of loss of smell and taste among the participants

Loss of smell was reported by 14 (30.4%) cases while loss of taste was reported by 8 (17.4%) cases. None of the controls reported loss of smell or taste (Table 2). There was a significant difference between cases and controls in the loss of smell (<0.001) and taste (0.006). Among the cases, there was no significant correlation between loss of smell and age (r = 0.023, p=0.879); sex (r = -0.132, p=0.382) and co-morbidities (r = - 0.028, p = 0.0.857). Similarly, there was no significant correlation between loss of taste and age (r = 0.052, p = 0.732); sex (0.040, p = 0.792) and comorbidities (r = -0.014, p = 0.925). Only reduction in hearing acuity was reported by five (10.9%) cases during infection but none of the controls had otologic symptoms. Table 4 showed the descriptive statistics of the cases’ subjective rating of their perception of smell, taste and hearing before and after COVID-19 diagnosis. There was an observed reduction in the mean score of their perception of smell, taste and hearing acuity after infection.
Table 4:

Subjective rating of perception of smell, taste and hearing before and after COVID-19 infection

Subjective rating of perception of sense of smell before diagnosis of COVID-19 Subjective rating of perception of sense of smell after diagnosis of COVID-19 Subjective rating of perception of sense of taste before diagnosis of COVID-19 Subjective rating of perception of sense of taste after diagnosis of COVID-19 Subjective rating of hearing acuity before diagnosis of COVID-19 Subjective rating of hearing acuity after diagnosis of COVID-19

Mean 7.86 6.08 8.92 6.90 7.6 7.2
Median 8.00 7.00 10.00 7.00 6 7
Mode 10 7 10 10 10 10
Std. Deviation 2.110 3.106 1.768 3.113 2.3 2.3
The status of sense of smell and taste as at the time of data collection was obtained from all the participants and shown in table 5 and table 6 respectively. There were 15 active cases, 14 recovering and 4 recovered COVID-19 cases.
Table 5:

Status of the sense of smell of COVID-19 positive adults

Progress of your sense of smellCurrent COVID-19 status of participants

Active No response
(n=15) Recovering (n=14) Recovered (n=4) (n=13) Total (n=46)

Improving 11 3 1 3 18
Worsening 1 1 0 1 3
No change 1 5 0 1 7
No response 2 5 3 818

Recovering cases refer to COVID-19 positive cases whose symptoms are abating

Recovered cases are COVID-19 positive patients who have turned asymptomatic.

Table 6:

Status of the sense of taste of COVID-19 positive adults

Progress of your sense of tasteCurrent COVID-19 status of participants

Active No response
(n=15) Recovering(n=14) Recovered(n=4) (n=13) Total(n=46)

Improving 6 3 0 0 9
Worsening 0 2 0 2 4
No change 6 5 2 3 16
Resolved 2 2 2 0 6
No response 1 2 0 8 11

Recovering cases refer to COVID-19 positive cases whose symptoms are abating

Recovered cases are COVID-19 positive patients who have turned asymptomatic

DISCUSSION

In this present study, our observation showed that the COVID-19 infection in Nigeria has affected both genders without bias, which is similar to what had been reported in the literature from other countries. The countries visited by the cases are locations where the burden of the disease is high.[14-16] To avoid transnational or transcontinental transmission during the pandemic, international travels were banned to curtail spread. Nonetheless, the cases which had already entered the country unnoticed led to the surge observed in the community. In this present study, 32.6% of cases migrated to Nigeria during the pandemic. About three quarters of the cases belong to the high socioeconomic class (Table 1). This is the class that can afford overseas travels for tourism, vacation, health, conference attendance etc. It is the reason for the erroneous belief that COVID-19 is a disease of the rich hence the uninformed hardly adhere and comply with the measures put in place by health workers and government to curtail spread of the infection. This might have also contributed to the increase in new cases being identified and reported in Nigeria. The study has shown that COVID-19 also affected those in lower socioeconomic class (48.1%) thereby nullifying this belief (Table 1). The symptomatology of COVID-19 (Tables 2-4) observed is similar to what had been reported in the literature.[3,17] The nasal cavities and oropharynx are the common portal of entry for SARS-COV-2 into the human body.[3] The interaction of the spike protein on the cell surface of the virus called protease transaminase protease serine 2 (TMPRSS2) and the Angiotensin Converting Enzyme 2 (ACE2 protein) receptor, which are abundantly expressed on the respiratory epithelium and its supporting olfactory cells in the nose allowed their adaptation, multiplication, invasion and propagation.[18,19] This partly explains the pathogenesis of the loss of smell in COVID-19 positive individuals. Patients with loss of smell usually complain of loss in taste. This is due to loss in contribution of smell to their perception of flavour. This hypothesis is implied in this report since there was no reported solitary case of loss of taste unlike loss of smell (Table 2 and 3). One could argue that taste loss in COVID-19 is due to smell loss rather than true pathologic taste loss as earlier posited by Fasunla and Ibekwe.[3] This evidence could explain the underlying pathogenetic mechanism of smell and taste loss in COVID-19. Underlying medical comorbidities have been shown to worsen the clinical course of COVID-19 by rapidly increasing the disease progression, making it to be more severe and often leading to death. In this study, there was no significant correlation between loss of smell or taste with medical comorbidities.[20] The prevalence of loss of smell in this study is 30.4%. Meta-analysis done by Tong et al.[14] and Costa et al.[15] on loss of smell among COVID-19 positive individuals reported pooled prevalence of olfactory dysfunction to be 52.73% and 60.7% respectively. The actual proportion of COVID-19 positive individuals that reported olfactory dysfunction in the studies used for the metanalysis ranged from 5.1% by Mao et al.[21] to 98.3% from Moein et al.[22] Table 4 showed a decrease in the mean of subjective rating of smell perception by the participants. Sudden loss of smell was the first symptom developed by about one-third of the participants making it an important marker or screening tool during COVID-19 pandemic. Individuals with symptom of sudden loss of smell could self-isolate before availability of RT-PCR result to prevent COVID-19 transmission. Sense of smell plays a significant role in the enjoyment of food, aroma, and also warns against danger especially with burnt cables, environment or spoilt food. In addition, it plays a vital role in our sexuality and emotions. Loss of sense of smell has been demonstrated to affect adversely the quality of life of an individual.[23] The symptom may further worsen the wellbeing of COVID-19 positive individuals. Although the risk of developing loss of smell has been reported to increase with age[24], there was no significant correlation between loss of smell and age of COVID-19 positive adults. The prevalence of loss of taste in this present study is 17.4%. The prevalence of loss of taste among COVID-19 positive individuals from different regions of the world ranged from 5.6% by Mao et al.[21] to 88.8% by Lechien et al.[8] Table 4 showed a decrease in the mean of subjective rating of taste perception by the participants. Optimal taste sensation is important in food enjoyment and compliance with medication which are essential in developing good immunity and satisfactory treatment outcomes. The wide range of proportion of COVID-19 positive individuals presenting with smell and taste loss from different studies might be related to different sample size and study designs. Olfactory training in those with loss of smell might also improve loss of taste as both have been shown to have a direct relationship.[25] This will also improve their wellbeing and quality of life. Otologic symptom has not been documented among COVID-19 positive adults as at the time of our study. One could hypothesise that inflammation of the nasal mucosa caused by its invasion by SARS-COV-2 could spread through the eustachian tube to affect the middle ear with resultant middle ear pathology leading to otologic symptoms. About 11% of the COVID-19 positive adults reported reduction in perception of sound during the infection. In addition, Table 4 showed a decrease in the mean of subjective rating of hearing acuity by the participants. The above finding is supported by a recent autopsy finding in two out of three deceased confirmed COVID-19 patients in the US, where SARS-COV-virus-2 was isolated in the middle ear and mastoid cavities.[10] The inflammatory process within the middle ear cleft could lead to exudate formation, otitis media with effusion (OME) and mastoiditis leading to conductive hearing loss. The limitation of this present study was the inability to clinically examine their ears for signs of OME and perform auditory test to confirm the reported hearing loss. Similarly, the virus is also known to be neurotropic and could therefore migrate into the inner ear to affect the vestibular or cochlear nerve with resultant hearing loss, tinnitus, dizziness or vertiginous spells. None of the cases presented with vestibular symptoms. The viral RNAs have also been isolated within the cerebrospinal fluid suggesting possible encephalitis which can affect the auditory center leading to a depreciated auditory perception.[26] It would have been better if this can be determined objectively. Further study on the hearing health of COVID-19 positive adults involving larger population and use of an objective audiological assessment method is hereby suggested.

CONCLUSION

Sudden loss of smell and taste are commoner among COVID-19 positive adults than those without the infection in Nigeria. There is an evidence of associated reduction in hearing acuity but further study with objective audiometric testing is recommended. Therefore, we recommend inclusion of sudden loss of smell and taste in the list of screening tools for identification of individuals with COVID-19 infection especially in sub-Saharan African where laboratory COVID-19 testing is still a challenge. Individuals with symptoms of sudden loss of smell and/or taste should be advised, as a matter of public health policy, to selfisolate prior to availability of RT-PCR result to prevent COVID-19 transmission in the community.

What is already known on the topic

Loss of smell and taste has been reported among COVID-19 patients. They were either known to be first symptom or part of the clinical presentations of individuals with positive COVID-19 test result. Footprint of SARS-CoV-2 found within the middle ear mucosal specimen of COVID-19 patients

What this study adds

To the best of our knowledge, it is the first scientific study on chemosensory function among COVID-19 positive individuals in Sub-Saharan Africa. Loss of smell and taste were also reported as first symptoms by some of these patients supporting the previous report. It also points to the possible involvement of the middle ear cleft by coronavirus infection which has been sparsely reported.
  22 in total

1.  Long term effects of olfactory training in patients with post-infectious olfactory loss.

Authors:  I Konstantinidis; E Tsakiropoulou; J Constantinidis
Journal:  Rhinology       Date:  2016-06       Impact factor: 3.681

Review 2.  Anosmia-A Clinical Review.

Authors:  Sanne Boesveldt; Elbrich M Postma; Duncan Boak; Antje Welge-Luessen; Veronika Schöpf; Joel D Mainland; Jeffrey Martens; John Ngai; Valerie B Duffy
Journal:  Chem Senses       Date:  2017-09-01       Impact factor: 3.160

Review 3.  Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19.

Authors:  Titus Sunday Ibekwe; Ayotunde James Fasunla; Adebola Emmanuel Orimadegun
Journal:  OTO Open       Date:  2020-09-11

4.  Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.

Authors:  Jerome R Lechien; Carlos M Chiesa-Estomba; Daniele R De Siati; Mihaela Horoi; Serge D Le Bon; Alexandra Rodriguez; Didier Dequanter; Serge Blecic; Fahd El Afia; Lea Distinguin; Younes Chekkoury-Idrissi; Stéphane Hans; Irene Lopez Delgado; Christian Calvo-Henriquez; Philippe Lavigne; Chiara Falanga; Maria Rosaria Barillari; Giovanni Cammaroto; Mohamad Khalife; Pierre Leich; Christel Souchay; Camelia Rossi; Fabrice Journe; Julien Hsieh; Myriam Edjlali; Robert Carlier; Laurence Ris; Andrea Lovato; Cosimo De Filippis; Frederique Coppee; Nicolas Fakhry; Tareck Ayad; Sven Saussez
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-06       Impact factor: 2.503

5.  Smell and taste dysfunction in patients with COVID-19.

Authors:  Michael S Xydakis; Puya Dehgani-Mobaraki; Eric H Holbrook; Urban W Geisthoff; Christian Bauer; Charlotte Hautefort; Philippe Herman; Geoffrey T Manley; Dina M Lyon; Claire Hopkins
Journal:  Lancet Infect Dis       Date:  2020-04-15       Impact factor: 25.071

6.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

Review 7.  Nervous system involvement after infection with COVID-19 and other coronaviruses.

Authors:  Yeshun Wu; Xiaolin Xu; Zijun Chen; Jiahao Duan; Kenji Hashimoto; Ling Yang; Cunming Liu; Chun Yang
Journal:  Brain Behav Immun       Date:  2020-03-30       Impact factor: 7.217

8.  Smell dysfunction: a biomarker for COVID-19.

Authors:  Shima T Moein; Seyed MohammadReza Hashemian; Babak Mansourafshar; Ali Khorram-Tousi; Payam Tabarsi; Richard L Doty
Journal:  Int Forum Allergy Rhinol       Date:  2020-06-18       Impact factor: 5.426

9.  Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms.

Authors:  Carol H Yan; Farhoud Faraji; Divya P Prajapati; Christine E Boone; Adam S DeConde
Journal:  Int Forum Allergy Rhinol       Date:  2020-06-01       Impact factor: 5.426

10.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Yi Zhao; Heng-Rui Liang; Zi-Sheng Chen; Yi-Min Li; Xiao-Qing Liu; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Chun-Quan Ou; Li Li; Ping-Yan Chen; Ling Sang; Wei Wang; Jian-Fu Li; Cai-Chen Li; Li-Min Ou; Bo Cheng; Shan Xiong; Zheng-Yi Ni; Jie Xiang; Yu Hu; Lei Liu; Hong Shan; Chun-Liang Lei; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Lin-Ling Cheng; Feng Ye; Shi-Yue Li; Jin-Ping Zheng; Nuo-Fu Zhang; Nan-Shan Zhong; Jian-Xing He
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

View more
  1 in total

1.  The Prevalence and Implications of Olfactory/Gustatory Dysfunctions among Adult COVID-19 Patients: A Retrospective Cohort Multiethnic Populations Study.

Authors:  Wael Hafez; Mahmoud Abdelshakor; Muneir Gador; Ikram Abdelli; Shougyat Ahmed
Journal:  Trop Med Infect Dis       Date:  2022-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.